Purchases this week followed a busy fourth quarter for biotech mergers and acquisitions, providing venture capitalists with returns as few companies are going public.
[
add
]
[
|
|
...
]
Purchases this week followed a busy fourth quarter for biotech mergers and acquisitions, providing venture capitalists with returns as few companies are going public.